Every Form 4 that MARIMED INC (MRMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRMD filings page.
MariMed Inc. director equity compensation update: Director Edward Gildea reported receiving 247,385 restricted stock units (RSUs) of MariMed Inc. common stock on December 5, 2025. These RSUs convert to common shares on a one-for-one basis and are scheduled to vest in full on December 15, 2025 under the terms of his award agreement with the company. The filing states that the RSUs were granted in lieu of cash for a portion of his fees for serving on the Board of Directors. Following this grant, Gildea is shown as beneficially owning 657,823 shares of MariMed common stock directly, and 247,385 derivative securities in the form of RSUs.
MariMed Inc. director David R. Allen reported an equity compensation grant in the form of restricted stock units (RSUs). On December 5, 2025, he received 176,389 RSUs, each of which converts into one share of MariMed common stock on a one-for-one basis. These RSUs were granted in lieu of cash for a portion of his fees for serving on the company’s Board of Directors.
The RSUs vest in full on December 15, 2025, according to the award agreement between MariMed and Allen. After this grant, he directly beneficially owned 299,755 shares of MariMed common stock and 176,389 RSUs, all held directly.
MariMed Inc. director reports new stock-based compensation grant
A MariMed Inc. (MRMD) director filed a Form 4 disclosing an award of 166,985 restricted stock units (RSUs) on December 5, 2025. Each RSU converts into one share of MariMed common stock, and the award vests in full on December 15, 2025 under the terms of the award agreement. The RSUs were granted in lieu of cash for a portion of the director’s board fees, meaning the director chose to receive equity instead of part of the normal cash compensation. Following this grant, the director reports 315,686 shares of common stock held directly and 166,985 RSUs directly beneficially owned. This filing highlights ongoing use of equity-based compensation to align director pay with company performance.
MariMed Inc. (MRMD) reported an insider equity transaction by its Chief Commercial Officer, Ryan Crandall. On 11/29/2025, Crandall exercised 75,000 restricted stock units (RSUs), which converted into an equal number of common shares at an exercise price of $0 per share. RSUs are a form of stock-based compensation that turn into common stock as they vest.
To cover tax withholding tied to this vesting, 22,013 common shares were withheld at a price of $0.0896 per share. After these transactions, Crandall beneficially owned 784,925 shares of MariMed common stock directly. The RSUs exercised came from a grant originally made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027 and November 29, 2027.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported equity transactions dated 11/29/2025. He exercised 93,750 restricted stock units (RSUs), which converted into the same number of common shares at an exercise price of $0, and then had 27,516 shares of common stock withheld at $0.0896 per share to cover tax obligations related to the RSU vesting.
After these transactions, Levine directly beneficially owns 21,072,715 shares of MariMed common stock and has an additional 6,684,640 shares held indirectly through the Jon Levine Family Trust, for which he disclaims beneficial ownership. He also continues to hold 187,500 RSUs, from a grant made on November 29, 2024, that are scheduled to vest in four equal installments between May 29, 2026 and November 29, 2027.
MariMed Inc. Chief Operating Officer Timothy Shaw reported equity transactions involving company stock. On 11/29/2025, 81,250 restricted stock units (RSUs) converted into the same number of MariMed common shares at an exercise price of $0, increasing his directly held shares. On the same date, 23,847 common shares were withheld by MariMed at a price of $0.0896 per share to cover tax obligations tied to the RSU vesting. After these transactions, Shaw directly owned 9,191,315 shares of common stock.
In addition, 2,000,000 MariMed shares are held indirectly through the Shaw Family Trust, an irrevocable trust for his children, for which his spouse is trustee and as to which he disclaims beneficial ownership. The RSUs that vested on November 29, 2025 were part of a grant made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027.
MariMed (MRMD) President & CEO Jon R. Levine reported equity award activity. On November 7, 2025, 75,000 RSUs converted into common stock (Code M) at $0, and 22,013 shares were withheld to satisfy taxes (Code F) at $0.097.
Following these transactions, he holds 21,006,481 shares directly and 6,684,640 shares indirectly by the Jon Levine Family Trust. 150,000 RSUs remain outstanding, scheduled to vest in equal installments on May 7, 2026 and November 7, 2026.